CEP57: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: CEP57

NCBI ID: G9702

CEP57

CEP57: A Potential Drug Target and Biomarker for Ovarian Cancer

Abstract:

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,000 new cases and 12,000 deaths in the United States alone every year. Despite advances in treatment, the survival rate for advanced ovarian cancer remains poor, highlighting the need for new and effective therapies. CEP57, a potential drug target and biomarker, has been identified as a promising target for the treatment of ovarian cancer. This article will discuss the biology of ovarian cancer, the development of CEP57 as a drug target, and its potential as a biomarker for the disease.

Introduction:

Ovarian cancer is a heterogeneous disease, with different subtypes that affect different stages and patient populations. Despite advances in the understanding of the genetic and molecular underpinnings of ovarian cancer, the treatment options for advanced disease remain limited. The development of new biomarkers and drug targets has the potential to significantly improve outcomes for ovarian cancer patients.

CEP57: A Potential Drug Target:

CEP57, short for protein 57 that crosses cell membranes, is a protein that is expressed in various tissues and cell types, including the uterus, breast tissue, and the brain. It is a member of the tyrosine kinase family and has been implicated in cell signaling, angiogenesis, and cancer progression.

Recent studies have suggested that CEP57 may be a potential drug target for ovarian cancer. Expression of CEP57 has been observed in various ovarian cancer cell types, including primary ovarian cancer, metastatic ovarian cancer, and ovarian cancer associated with bad eggs (BRCA) mutations. Additionally, inhibition of CEP57 has been shown to enhance the sensitivity of ovarian cancer cells to chemotherapy, suggesting that it may have a unique mechanism of action in ovarian cancer treatment.

CEP57 as a Biomarker:

The identification of biomarkers for ovarian cancer has the potential to improve diagnosis, prognosis, and treatment outcomes. CEP57 is a potential biomarker for ovarian cancer due to its expression in various ovarian cancer cell types and its potential as a drug target.

Currently, there are few biomarkers that have been identified for ovarian cancer that have been shown to be effective in clinical trials. One of the most promising biomarkers is the gRG1, which is a gene expression signature that has been associated with ovarian cancer progression. Another biomarker that has potential is the MUC1, which is a gene that has been implicated in the development of ovarian cancer.

CEP57 has the potential to be a more effective biomarker for ovarian cancer than gRG1 or MUC1, as it has been shown to be expressed in various ovarian cancer cell types and has been linked to the development of ovarian cancer. Additionally, CEP57 has been shown to be a potential drug target for ovarian cancer, which could lead to new therapeutic options for the treatment of ovarian cancer.

Conclusion:

CEP57 is a protein that has been identified as a potential drug target for ovarian cancer. Its expression has been observed in various ovarian cancer cell types and has been linked to the development of ovarian cancer. Additionally, CEP57 has the potential to be a more effective biomarker for ovarian cancer than existing biomarkers. Further research is needed to determine its role in the treatment of ovarian cancer and to develop new therapeutic options for this disease.

Protein Name: Centrosomal Protein 57

Functions: Centrosomal protein which may be required for microtubule attachment to centrosomes. May act by forming ring-like structures around microtubules. Mediates nuclear translocation and mitogenic activity of the internalized growth factor FGF2, but that of FGF1

The "CEP57 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP57 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets